If the product is mixed improperly or used on broken skin without guidance, irritation risk may increase
Nat Rev Nephrol 22 , 265282 (2026)
However, there are several ways to examine fracture-related outcomes under GLP-1Ra
But supplements should be used with caution
Structures, Indications, and Dosages of GLP-1 RAs and a Dual GLP-1/GIP RA Exenatide Exenatide is the first-in-class incretin mimetic drug.34 It is a 39 amino acid (aa)-long synthetic peptide drug (Figure 1C), derived from exendin-4 (Figure 1B), a peptide isolated from the saliva of the lizard Heloderma suspectum .4,35 The immediate-release (IR) formulation of exenatide (Byetta , Amylin Pharmaceuticals, San Diego, CA, USA) was first developed in 2005 to treat type 2 diabetes (Table 1).34 Initial dosing regimen of Byetta is 5 g subcutaneously twice daily and after one month, the dose is increased to 10 g twice daily based on clinical response (Table 1).36 In 2012, the extended-release (ER) formulation of exenatide (Bydureon , Amylin Pharmaceuticals) was approved by the US FDA to treat type 2 diabetes mellitus.37 Bydureon Pen (AstraZeneca, Wilmington, DE, USA) and Bydureon BCise (AstraZeneca) were developed later, but currently, only the latter, an enhanced injector pen formulation, is prescribed.38 The dosing regimen of Bydureon BCise is 2 mg once weekly subcutaneously (Table 1).38 Liraglutide Liraglutide is a 31 aa-long synthetic peptide drug attached to 16 carbon fatty acids (MW: 3751 g/mol) (Figure 1D).39 It was approved by the US FDA in 2014 to treat obesity (Saxenda , Novo Nordisk, Plainsboro, NJ, USA), after first being approved as a type 2 diabetes medication (Victoza , Novo Nordisk) in 2010 (Table 1)
Some patients experience mild facial volume loss, while others develop more significant loose skin after larger transformations
